Skip to main content
. 2024 Jan 5;43(8):578–593. doi: 10.1038/s41388-023-02926-w

Fig. 4. MY-COMP inhibits YAP-driven liver tumorigenesis.

Fig. 4

A Scheme of the HDTVI-based mouse model of liver tumorigenesis. Vectors encoding Myr-AKT and GFP-IRES-YAP5SA or Myr-AKT and MY-COMP-IRES-YAP5SA were injected along with the SB transposase into the tail vein of C57BL/6 mice. Liver tumor formation was assessed 6 weeks later. SB100 sleeping beauty transposase, ITR inverted terminal repeat. B Top: Representative images of whole livers from mice injected with the indicated constructs. Bottom: Representative H&E images of the two groups. Scale bars: 1 cm. C Ratio of liver to body weight of the indicated groups. Welch t-test. D Quantification of tumor area relative to the whole liver area. Welch t-test. GFP (n = 9), MY-COMP (n = 8).